As per late-stage data from US based clinical trial Novavax Inc on monday, showing it’s Coronavirus vaccine is more than 90% effective across a variety of variants of the virus.
The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.
“Novavax is one step closer to addressing the critical and persistent global public health need for additional Covid-19 vaccines,” Chief Executive Officer Stanley C. Erck said in a statement. “Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.”
The vaccine uses a recombinant protein technology, also used in the vaccine candidate developed by Sanofi and GlaxoSmithKline Plc. At over 90%, the overall efficacy of the vaccine is close to reported rates for mRNA shots developed by Pfizer Inc. with BioNTech SE and by Moderna Inc., as well as the Sputnik V vaccine from Russia, using viral vector technology.
However, immunologists tend to caution against comparing efficacy results across different trials as conditions and evaluation methods aren’t the same.
The company previously said it wouldn’t file for vaccine authorization in the U.S. and Europe until the third quarter of the year. Novavax says it’s on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million per month by the end of 2021.
